These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34403732)

  • 1. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
    Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
    Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
    Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
    Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based Virtual Screening from Natural Products as Inhibitors of SARS-CoV-2 Spike Protein and ACE2 Receptor Binding and their Biological Evaluation
    Delgado-Maldonado T; Gonzalez-Morales LD; Juarez-Saldivar A; Lara-Ramírez EE; Rojas-Verde G; Moreno-Rodriguez A; Bandyopadhyay D; Rivera G
    Med Chem; 2024; 20(5):546-553. PubMed ID: 38204279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
    Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
    Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
    Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
    PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice.
    Pan H; He J; Yang Z; Yao X; Zhang H; Li R; Xiao Y; Zhao C; Jiang H; Liu Y; Li Z; Guo B; Zhang C; Li RZ; Liu L
    Phytomedicine; 2023 Jul; 116():154858. PubMed ID: 37224774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
    Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein.
    Eskandari V
    J Mol Model; 2022 May; 28(6):153. PubMed ID: 35578055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Potential Allosteric Site in the SARS-CoV-2 Spike Protein and Targeting Allosteric Inhibitor to Stabilize the RBD Down State using a Computational Approach.
    Li T; Yan Z; Zhou W; Liu Q; Liu J; Hua H
    Curr Comput Aided Drug Des; 2024; 20(6):784-797. PubMed ID: 37493168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction.
    Kim YS; Kwon EB; Kim B; Chung HS; Choi G; Kim YH; Choi JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
    Lee RK; Li TN; Chang SY; Chao TL; Kuo CH; Pan MY; Chiou YT; Liao KJ; Yang Y; Wu YH; Huang CH; Juan HF; Hsieh HP; Wang LH
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.